Not finding it? Sign in to also search OpenAlex live.
-
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT
Piera Angelillo, Ana Alarcón Tomás, Edoardo Campodonico, Urban Novak, Ludovic Gabellier, Igor Wolfgang Blau, +24 more
7citations -
P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE
A. M. Spanjaart, Elise R. A. Pennings, Pim G. N. J. Mutsaers, Suzanne van Dorp, Margot Jak, J. van Doesem, +11 more
1citations -
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
Anne Mea Spanjaart, Elise R. A. Pennings, Pim G. N. J. Mutsaers, Suzanne van Dorp, Margot Jak, Jaap A. van Doesum, +14 more
23citations -
High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Sébastien Anguille, Maria Theresa Kuipers, Évelyne Willems, Tim J. A. Dekker, +14 more
2citations -
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Marie José Kersten, Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Maria Theresa Kuipers, Évelyne Willems, Sébastien Anguille, +14 more
3citations -
Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne Mea Spanjaart, Per T Ljungman, Rafael de la Cámara, Gloria Tridello, Valentín Ortiz‐Maldonado, Álvaro Urbano-Ispizúa, +28 more
16citations -
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne Mea Spanjaart, Per T Ljungman, Rafael de la Cámara, Gloria Tridello, Valentín Ortiz‐Maldonado, Álvaro Urbano-Ispizúa, +28 more
115citations -
Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Letícia Alserawan, Sergi Betriu, Ana Triguero, Sandra Blum, +8 more
5citations -
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy2020 Bone Marrow Transplantation article Medicine Hematopoietic Stem Cell Transplantation Open access
Per T Ljungman, Małgorzata Mikulska, Rafael de la Cámara, Grzegorz Władysław Basak, Christian Chabannon, Selim Corbacioglu, +12 more
215citations -
Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort
Hilde T. van der Galiën, Pim G. N. J. Mutsaers, Margot Jak, Marjolein van der Poel, Marije T. Nijk, Kees Meijer, +13 more
0citations -
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study
Marie José Kersten, Maria Theresa Kuipers, Pim G. N. J. Mutsaers, Évelyne Willems, Kirsten Saevels, Martin H. Dreyling, +14 more
0citations -
Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Marie José Kersten, Kirsten Saevels, Évelyne Willems, Marte C. Liefaard, Stavros Milatos, Margot J. Pont, +9 more
3citations -
Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy2020 Bone Marrow Transplantation erratum Medicine Hematopoietic Stem Cell Transplantation Open access
Per T Ljungman, Małgorzata Mikulska, Rafael de la Cámara, Grzegorz Władysław Basak, Christian Chabannon, Selim Corbacioglu, +12 more
14citations -
Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation
Giorgio Orofino, Isabel Sánchez‐Ortega, Juana Schwartz Mota, Andrea Aroldi, Cristina Castilla‐Llorente, Camille Bigenwald, +33 more
0citations